Skip to main content

Table 4 Thrombotic Events, Cardiovascular Events, and Deaths Occurring During the Follow-Up Period

From: Cytoreductive treatment patterns among US veterans with polycythemia vera

Event Patients With ≥1 Event, n (%) Mean Time to First Event, y Patient-Yearsa Event Rate, per 1000 Patient-Yearsb 95% CI of Event Rate
Among all patients with PV (N = 7718)
Thrombotic event 1771 (22.9) 1.4 29,276.2 60.5 57.7–63.4
 Arterial 1275 (16.5) 1.5 30,874.3 41.3 39.1–43.6
  Ischemic stroke 825 (10.7) 1.4 32,216.2 25.6 23.9–27.4
  Transient ischemic attack 344 (4.5) 1.6 33,609.5 10.2 9.2–11.4
  Acute myocardial infarction 224 (2.9) 2.3 34,167.1 6.6 5.8–7.5
  Peripheral arterial thrombosis 109 (1.4) 2.0 34,364.7 3.2 2.6–3.8
 Venous 678 (8.8) 1.4 32,621.4 20.8 19.3–22.4
  Deep vein thrombosis 535 (6.9) 1.4 32,992.0 16.2 14.9–17.7
  Pulmonary embolism 234 (3.0) 1.7 34,029.2 6.9 6.1–7.8
  Superficial thrombophlebitis 42 (0.5) 1.9 34,529.8 1.2 0.9–1.7
Cardiovascular event 2325 (30.1) 1.4 27,750.5 83.8 80.4–87.3
  Heart failure 1442 (18.7) 1.5 30,730.4 46.9 44.6–49.4
  Ischemic stroke 825 (10.7) 1.4 32,216.2 25.6 23.9–27.4
  Transient ischemic attack 344 (4.5) 1.6 33,609.5 10.2 9.2–11.4
  Acute myocardial infarction 224 (2.9) 2.3 34,167.1 6.6 5.8–7.5
  Unstable angina 185 (2.4) 2.3 34,193.5 5.4 4.7–6.3
  Percutaneous coronary intervention 78 (1.0) 2.0 34,444.8 2.3 1.8–2.8
  Coronary artery bypass graft 7 (0.1) 2.0 34,624.2 0.2 0.1–0.4
Mortality 1776 (23.0) 2.8 34,684.6 51.2 48.9–53.6
Among patients with PV receiving cytoreductive treatment (n = 1522)
Thrombotic event 295 (19.4) 2.2 6032.3 48.9 43.6–54.8
Among patients with PV not receiving cytoreductive treatment (n = 6196)
Thrombotic event 1476 (23.8) 1.2 23,243.8 63.5 60.3–66.8
  1. PV polycythemia vera
  2. aUp to the first respective event after diagnosis or end of the study period, whichever occurred first
  3. bRate per 1000 patient-years was defined as 1000 × number of patients with first event/patient-years of total patients with PV